Athersys (NASDAQ:ATHX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday.

Several other brokerages also recently commented on ATHX. Maxim Group set a $12.00 target price on Athersys and gave the stock a “buy” rating in a research note on Thursday, October 5th. Zacks Investment Research downgraded Athersys from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Athersys has an average rating of “Hold” and an average target price of $7.17.

Shares of Athersys (ATHX) traded down $0.08 during midday trading on Tuesday, hitting $1.85. The stock had a trading volume of 495,540 shares, compared to its average volume of 1,024,704. Athersys has a one year low of $1.02 and a one year high of $2.63.

In other news, EVP John J. Harrington sold 15,000 shares of Athersys stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $2.17, for a total transaction of $32,550.00. Following the completion of the transaction, the executive vice president now directly owns 679,416 shares in the company, valued at approximately $1,474,332.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ATHX. Bank of America Corp DE lifted its holdings in Athersys by 17.2% during the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 9,019 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Athersys by 329.7% during the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 56,345 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in Athersys during the 2nd quarter worth approximately $113,000. Blair William & Co. IL lifted its holdings in Athersys by 708.0% during the 2nd quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 70,804 shares during the last quarter. Finally, Thompson Davis & CO. Inc. lifted its holdings in Athersys by 743.9% during the 3rd quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 56,683 shares during the last quarter. 21.06% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/05/athersys-athx-downgraded-by-valuengine-to-sell.html.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.